The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 30, 2021
Filed:
Jun. 17, 2019
Applicant:
Intra-cellular Therapies, Inc., New York, NY (US);
Inventors:
Kimberly Vanover, New York, NY (US);
Peng Li, New Milford, NJ (US);
Sharon Mates, New York, NY (US);
Robert Davis, San Diego, CA (US);
Lawrence P. Wennogle, Hillsborough, NJ (US);
Assignee:
INTRA-CELLULAR THERAPIES, INC., New York, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/5383 (2006.01); A61K 31/4985 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61K 9/51 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5383 (2013.01); A61K 9/0019 (2013.01); A61K 9/0024 (2013.01); A61K 9/5153 (2013.01); A61K 31/4985 (2013.01); A61K 45/06 (2013.01);
Abstract
The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.